Edarbyclor — Medica
management of heart failure (NYHA Class II to IV) in patients unable to swallow valsartan tablets
Preferred products
- candesartan
- candesartan/HCTZ
- eprosartan
- irbesartan
- irbesartan/HCTZ
- losartan
- losartan/HCTZ
- telmisartan
- telmisartan/amlodipine
- telmisartan/HCTZ
- olmesartan
- olmesartan/amlodipine
- olmesartan/HCTZ
- olmesartan/amlodipine/HCTZ
- valsartan
- valsartan/amlodipine
- valsartan/HCTZ
- valsartan/amlodipine/hydrochlorothiazide
Initial criteria
- Patient has tried one Step 1 Product; OR
- Patient meets all of the following: (A) The generic equivalent is not available in Step 1; AND (B) Patient was hospitalized and discharged within the previous 30 days for a cardiovascular event (e.g., myocardial infarction, hypertensive emergency, decompensated heart failure); AND (C) Patient has been started and stabilized on the Step 2 Product; OR
- Patient cannot swallow or has difficulty swallowing tablets (approve Prexxartan)
Approval duration
1 year